GlassScriptPhysician profile
Sarah Kendroud
NPI 1194221143
$41,585.30
in general payments reported to CMS, 2019-2025
9 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $26K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $40K · Travel and Lodging: $983 · Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $40,000.00 |
| Travel and Lodging | $982.50 |
| Food and Beverage | $602.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $31,196.86 | 2024-2025 | Activa PC, Percept PC Brainsense |
| Boston Scientific Corporation | $10,020.77 | 2024 | Vercise |
| Biogen, INC. | $121.89 | 2024 | |
| Argenx US, INC. | $70.81 | 2023 | Vyvgart |
| Amneal Pharmaceuticals LLC | $65.14 | 2025 | |
| Abbvie INC. | $49.55 | 2023 | |
| Ge Healthcare | $29.21 | 2025 | |
| Averitas Pharma INC. | $16.13 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $14.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kendroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.